Supplementary material to article by X. Wen et al. “Facial Manifestations of Pachydermoperiostosis Treated with Botulinum Toxin Type-A: Report of 3 Cases”

Fig. S1. Injection sites and doses for patients with PDP. (a) BTX-A was injected into procerus muscle (single spot, 5U), the *corrugator supercili* muscles (2 spots, medially at the site of their attachment to the bone using 5U each, and laterally at the skin insertion sites using 4U each) for patient 1. (b) The procerus muscle (single spot, 10U), the *corrugator supercili* muscles (2 spots, medially at the site of their attachment to the bone using 7U each and laterally at the skin insertion sites using 5U each), forehead (7 intradermal injections along the furrows using 3U each) and the lateral tail of each eyebrow (3U each) for patient 2. (c) Sites and doses in the glabellar region were the same as case 1, 5 intradermal injections along the forehead were given using 2U each for patient 3.